Istituto Gentili is committed to establishing itself in the national pharmaceutical scenario as a reliable partner for collaboration agreements with multinational pharmaceutical companies present in oncology area. Istituto Gentili enriched its portfolio thanks to:

• Cooperation agreement with Novartis Farma S.p.A (2017) for the marketing and distribution in Italy of lapatinib, a molecule indicated for the treatment of a particularly aggressive form of breast cancer, characterized by high levels of the HER2 receptor.
  
  
• Acquisition of Therabel Gienne Pharma, the Italian branch of Dutch company Therabel (2017), by joining to its portfolio a product for the treatment of oropharyngeal candidiasis (topical miconazole), a condition very frequent in immunodepressed patients following chemotherapy regimens.
  
  
• Partnership with Teva Italia Srl OncoCare (2018), which allowed Istituto Gentili to expand in the oncological area by adding a drug for the treatment of metastatic breast cancer (liposomal doxorubicin), and two supportive therapies for the treatment of neutropenia (lipegfilgrastim) and intense episodic pain (fentanyl citrate), two conditions associated with oncological disease.
  Thanks to this partnership, Istituto Gentili has strengthened its role as one of the main players in the pharmaceutical scenario, with the aim to improve the quality of human life by providing innovative therapeutic solutions in oncology and onco-hematology disease areas.